Table 1 Clinical characteristics of the study patients.
From: Radiomics prognostication model in glioblastoma using diffusion- and perfusion-weighted MRI
Parameter | Training set (n = 158) | External validation set (n = 58) | P value |
|---|---|---|---|
Sex, n | 0.52 | ||
Male/Female | 96/62 | 38/20 | |
Age, years | 0.27 | ||
Median (range) | 59.5 (31–83) | 57.6 (20–80) | |
Primary treatment, n [%] | |||
Extent of resection | 0.12 | ||
Gross-total resection | 72 (45.6%) | 34 (58.6%) | |
Subtotal resection | 57 (36.1%) | 19 (32.8%) | |
Biopsy | 29 (18.4%) | 5 (8.6%) | |
Adjuvant treatment | |||
RT + TMZ | 141 (89.2%) | 58 (100%) | 0.07 |
Other | |||
RT only | 1 (0.6%) | 0 | |
TMZ only | 4 (2.5%) | 0 | |
No RT or TMZ | 12 (7.6%) | 0 | |
Location | 0.62 | ||
Frontal or temporal | 73 (46.2%) | 29 (50%) | |
Others | 85 (53.8%) | 29 (50%) | |
KPS at treatment initiation, n (%) | 0.64 | ||
≥70 | 138 (87.3%) | 52 (89.7%) | |
<70 | 20 (12.6%) | 6 (10.3%) | |
MGMT promoter status, n (%) | |||
Methylated | 12 (7.6%) | 28 (48.3%) | 0.13 |
Unmethylated | 25 (15.8%) | 19 (32.7%) | |
NA | 120 (75.9%) | 11 (19.0%) | NA |
Median follow-up time, years range) | 2.86 (1.06–5.67) | 4.47 (3.44–6.18) | 0.047 |
